Why the study?
Does combination therapy with an ACE inhibitor and an ARB increase the risk of adverse renal outcomes and hyperkalemia compared to monotherapy in elderly patients?
Does combination therapy with an ACE inhibitor and an ARB increase the risk of adverse renal outcomes and hyperkalemia compared to monotherapy in elderly patients?
Combining ACE inhibitors and ARBs in elderly patients is associated with a significantly increased risk of renal dysfunction and hyperkalemia compared to monotherapy, often without established clinical indications.
Answers are grounded in this paper and cite their sources.
May warrant avoiding unindicated ACEI/ARB combinations in elderly patients; leaves open causality and generalizability pending randomized confirmation.
BACKGROUND: The risks associated with using an angiotensin-converting-enzyme (ACE) inhibitor and an angiotensin-receptor blocker together are unclear. This study was designed to determine the safety of combination therapy with these two drugs in clinical practice. METHODS: We conducted a population-based longitudinal analysis using linked administrative and laboratory data for elderly patients who were new users of an ACE inhibitor, an angiotensin-receptor blocker or a combination of both medications between May 1, 2002, and Dec. 31, 2006. We compared outcomes in patients given combination therapy versus patients given monotherapy using Cox proportional hazards analyses with adjustment for baseline characteristics. RESULTS: Of the 32,312 new users of either medication (mean age 76.1 years, median creatinine level 92 μmol/L), 1750 (5.4%) received combination therapy. However, 1512 (86.4%) of the patients who were given combination therapy did not have trial-established indications such as heart failure or proteinuria. Renal dysfunction was more common among patients given combination therapy (5.2 [95% confidence interval (CI) 3.4 to 7.9] events per 1000 patients per month) than among patients given monotherapy (2.4 [95% CI 2.2 to 2.7] events per 1000 patients per month) (adjusted hazard ratio [HR] 2.36, 95% CI 1.51 to 3.71). Hyperkalemia was also more common among patients given combination therapy (2.5 [95% CI 1.4 to 4.3] events per 1000 patients per month) than among patients given monotherapy (0.9 [95% CI 0.8 to 1.0] events per 1000 patients per month) (adjusted HR 2.42, 95% CI 1.36 to 4.32). Most patients took combination therapy for only a short time (median three months before at least one agent was stopped). INTERPRETATION: Combination therapy was frequently prescribed for patients without established indications and was associated with an increased risk of adverse renal outcomes when compared with monotherapy. These results mirrored data from randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
McAlister et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: